The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...

A research team at the University of Konstanz, led by toxicologist Ivano Amelio, has demonstrated how differently individual mutations of the tumor suppressor p53 affect pancreatic carcinomas. When ...

TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

Frontier Medicines Corp. has announced the selection of FMC-220, a first-in-class covalent small-molecule activator of p53 Y220C designed to address potency and tolerability challenges of noncovalent ...

Researchers have uncovered a mechanism that allows breast cancer to send metastases to the brain, potentially enabling the ...

The discovery could pave the way for new treatments, improved risk prediction, and earlier intervention for brain metastases.